
Opinion|Videos|March 7, 2025
RCC Treatment Selection: Expert Perspectives on Long-Term Data and Insights on Treatment Selection
Experts discuss key factors influencing the decision between immunotherapy (IO)/IO and various IO/tyrosine kinase inhibitor (TKI) combinations in advanced renal cell carcinoma (RCC) treatment, including patient characteristics, risk stratification, PD-L1 status, and other clinical features, while also exploring the patient experience with IO-TKI regimens, strategies for managing adverse effects, and the approach to hepatotoxicity management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- When you’re evaluating treatment options for your advanced RCC patients today, what key factors drive your decision between the IO/IO approach with ipilimumab/nivolumab vs the various IO/TKI combinations like pembrolizumab/lenvatinib, pembrolizumab/axitinib, nivolumab/cabozantinib, or avelumab/axitinib? How do you weigh patient characteristics, risk stratification, PD-L1 status, and other clinical features in this decision?
- Dr Barata asks Dr Beckermann:Briefly discuss your perspective on the patient experience for patients undergoing IO/TKI regimens and explore strategies for their mitigation and management.
- Comment on how patterns of hepatoxicity differ across trials and discuss your general approach to management.
Advertisement
Related to this article

The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.

Daraxonrasib plus gemcitabine/nab-paclitaxel yielded a 60.7% ORR and 12.8-month median PFS in first-line metastatic pancreatic adenocarcinoma.

Sac-TMT improved OS vs treatment of physician’s choice in pretreated gastroesophageal adenocarcinoma, but TroFuse-015 missed its PFS secondary end point.

Gynecologic oncologists answer FAQs on LGSOC targeted therapy, PARP inhibitor maintenance, and emerging ADCs in ovarian cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Jorge Cortes, MD, discusses response-based ponatinib dosing, mutation testing, and managing cardiovascular risk in resistant CML.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Leighl on HARMONi Survival Data and the FDA's Decision on Ivonescimab in Previously Treated EGFR-Mutated NSCLC
5



